Mayukh Sukhatme Sells 412,584 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CIO Mayukh Sukhatme sold 412,584 shares of the company's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the completion of the transaction, the executive now owns 18,836,547 shares in the company, valued at $226,980,391.35. This represents a 2.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Roivant Sciences Stock Performance

Roivant Sciences stock traded up $0.07 during mid-day trading on Friday, reaching $11.57. 15,754,118 shares of the company were exchanged, compared to its average volume of 5,795,466. Roivant Sciences Ltd. has a 12-month low of $9.69 and a 12-month high of $13.06. The business has a fifty day moving average of $11.91 and a 200 day moving average of $11.48. The firm has a market cap of $8.42 billion, a P/E ratio of 2.05 and a beta of 1.25.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ROIV. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. Bank of America lifted their target price on Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a research report on Wednesday, September 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 19th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $17.93.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors have recently added to or reduced their stakes in the stock. TOMS Capital Investment Management LP acquired a new stake in Roivant Sciences in the third quarter valued at approximately $46,333,000. Rubric Capital Management LP boosted its position in shares of Roivant Sciences by 15.0% in the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company's stock worth $243,110,000 after purchasing an additional 3,000,000 shares in the last quarter. Troluce Capital Advisors LLC purchased a new position in Roivant Sciences during the 2nd quarter worth $31,182,000. FMR LLC increased its position in Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock valued at $567,134,000 after buying an additional 2,593,910 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Roivant Sciences by 23.2% in the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock valued at $89,400,000 after buying an additional 1,460,205 shares during the last quarter. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.